期刊文献+

顺铂水针剂与粉针剂体外细胞毒作用的差异性研究 被引量:5

The comparison of the cytotoxicity between cisplatin solution and cisplatin powder in vitro
下载PDF
导出
摘要 目的:比较两种不同剂型顺铂针剂的细胞毒效应。方法:用含不同终浓度顺铂水针剂与粉针剂的培养液培养Hela细胞系,采用四甲基偶氮唑蓝比色法(MTT)检测细胞存活率并计算顺铂的50%抑制浓度(IC50),分析比较两种不同顺铂剂型针剂在体外的细胞毒效应。结果:相对于顺铂粉针剂,相同终浓度顺铂水针剂作用的Hela细胞存活率较低,其IC50值分别为(14.01±0.07)μg·ml-1及(15.03±0.26)μg·ml-1(P=0.003)。其中在(0.1、1、10)μg.ml-1组中细胞存活率存在差异。结论:顺铂水针剂较粉针剂体外细胞毒效应强。 Objective:To compare the cytotoxicity between cisplatin solution and cisplatin powder in vitro. Methods:Hela, human cell line, was cultured in Dulbecco's modified Eagleg medium (DMEM) containing 10% Neonatal Bovine Serum with or without various concentrations of cisplatin came from solution or powder . Cell viability was examined by methylthiazolyl tetrazolium (MTT) assay and 50% inhibitive concentration( IC50 ) of cisplatin was examined. Cytotoxicity of cisplatin solution and cisplatin powder in vitro was compared using Student's t - test. Results: Compared with cisplatin powder group, at the same concentration of cisplatin, in cisplatin solution group, cell viability declined and the 50% inhibitory concentration ( IC50 ) of DDP for cisplatin solution was ( 14.01 ± 0.07) μg · ml^-1 and IC50 of DDP for cisplatin powder was ( 15.03 ± 0.26) μg · ml^-1 ( p = 0. 003 ). Conclusion: Compared with cisplatin powder, cisplatln solution has a higher cytotoxicity effect in vitro.
出处 《现代肿瘤医学》 CAS 2008年第7期1101-1102,共2页 Journal of Modern Oncology
关键词 顺铂 剂型 细胞毒效应 cisplatin preparation cytotoxicity
  • 相关文献

参考文献11

  • 1Jordana P, Carmo -Fonsecab M. Molecular mechanisms involved in cisplatin cytotoxicity[ J]. Cell and Mol Life Sci,2000,57:1229 - 1235.
  • 2Maurie Markman. New, expanded, and modified use of approved antineoplastic gents in ovarian cancer[ J]. Oncologist, 2007,12: 186 - 190.
  • 3Pier Luigi Zorat, Adriano Paeeagnella, Gianearlo Cavaniglia. Randomized phase Ⅲ trial of neoadjuvant chemotherapy in head and neck cancer: 10 - year follow - up[J]. J Natl Cancer Institute, 2004 ,96(22) :1647 - 1649.
  • 4Christensen TB, Daugaard G, Geertsen PF, et al. Effect of chemotherapy on carcinoma in situ of the testis[J].Ann Oncol, 1998 , 9(6) :657 -660.
  • 5Strumberg D, Brugge S, Korn MW, et al. Evaluation of long - term toxicity in patients after cisplatin - based chemotherapy for non - seminomatous testicular cancer [ J ]. Annals of Oncol, 2002,13 : 229 - 236.
  • 6Gholam D, Fizazi K,Terrier-Lacombe MJ. Advanced seminoma- treatment results and prognostic factors for survival after first - line, cisplatin -based chemotherapy and for patients with recurrent disease : a single - institution experience in 145 patients [ J ]. Cancer, 2003 ,98(4) :745 -752.
  • 7Heather Wakelee, Chandra P Belani. Optimizing first - line treatment options for patients with advanced NSCLC [ J ]. Oncologist, 2005,10:1 - 10.
  • 8Abratt RP, Hart GJ. 10 -year update on chemotherapy for non - small cell lung cancer [ J ]. Ann Oncol,2006,17 (Suppl 5 ) :33 - 36.
  • 9Carvalho Junior AD, Vieiral FP, De Melo VJ. Preparation and cytotoxicity of cisplatin - containing liposomes [ J ]. Brazilian J Med and Biol Res ,2007, 40 : 1149 - 1157.
  • 10Velinova MJ, Staffhorst RW, Mulder WJ, et al. Preparation and stability of lipid - coated nanooapsules of cisplatin : anionic phospholipid speciflcity[J]. Biochim Biophys Acta,2004 ,1663(1 - 2 ) : 135 - 142.

二级参考文献22

  • 1Smith, O'Brien, Talbot, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol, 2001,19(5):1336
  • 2Rauko, Novotny, Dovinova, et al. Ntitumor activity of benzamide riboside and its combination with cisplatin and staurosporine. Eur J Pharm Sci, 2001,12(4) :387
  • 3Sandler , Bhimma R, Coovadia M, et al. Irinotecan: future directions in small-cell lung cancer. Clin Lung Cancer, 2001 ,S2:9
  • 4Bogush,Konukhova,Tillmann H L. Inhibition of ABC-transporter (s)' function in non-small cell lung cancer cells by platinum drugs.Antibiot Khimioter, 2003,48(10): 11
  • 5Meric,Rixe,Khayat. Metastatic malignant melanoma. Drugs Today (Barc), 2003,39 (S-C) : 17
  • 6Curran , Sawayama Y, Hayashi J. Combined-modality therapy for inoperable non-small-cell lung cancer using gemcitabine. Clin Lung Cancer, 2002,3:S17
  • 7Janne , Skarin, Gucer S. Concurrent docetaxel and thoracic radiation in non-small-cell lung cancer. Clin Lung Cancer, 2002,3 (2):S37
  • 8Rosell, Taron , O'Brate et al. Predictive molecular markers in non-small cell lung cancer. Curr Opin Oncol, 2001,13 (2): 101
  • 9Loehrer , Wick J. Thymic malignancies in non-small cell lung cancer. Cancer Treat Res, 2001,105 (2): 277
  • 10Nishioka, Kawakami Y, Adhikari M. Duration of chemotherapy in advanced non-small-cell lung cancer. Jpn J Cancer Chemother,1994,19(3):120

共引文献6

同被引文献37

引证文献5

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部